VEGF Promoter Region 18-bp Insertion-Deletion Polymorphism in Sickle Cell Disease Patients with Microalbuminuria: A Pilot Study

  • Dnyanesh B. AmleEmail author
  • Rachana L. Patnayak
  • Varsha Verma
  • Gajendra Kumar Singh
  • Vijaylakshmi Jain
  • P. K. Khodiar
  • P. K. Patra
Original Article



Vascular endothelial growth factor (VEGF) is a potent inducer of micro vascular permeability thus leading to nephropathy. Insertion/deletion (I/D) polymorphism of 18 bp at − 2549 position in VEGF gene causes increased transcription leading to increased production of VEGF. Thus, we aimed to associate I/D polymorphism of the 18 bp fragment at − 2549 position of the promoter region of VEGF gene with sickle cell nephropathy (SCN).


This observational analytical case control study included 30 subjects each of SCN, sickle cell disease (SCD) without nephropathy and the control group. The subjects were assessed for various hematological and biochemical parameters. Further, 18 bp I/D polymorphism of VEGF gene in all three study groups was assessed by polymerase chain reaction followed by electrophoresis and compared.


Though increased frequency of both DD genotype and D allele was found in SCN compared to SCD and control, only frequency of D allele was found to be significantly higher (p = 0.04). D allele posed marginal risk of microalbuminuria in SCD subjects compared to controls (OR = 2.11) as well as to SCD without MA subjects (OR = 1.84).


D allele in I/D polymorphism in the promoter region of VEGF gene may be associated with marginal increase in risk of susceptibility to sickle cell nephropathy.


Sickle cell disease Sickle cell nephropathy VEGF Polymorphism 


Compliance with Ethical Standards

Conflict of interest

All authors declare that there is no conflict of interest related to the work.

Ethical Approval

The study was conducted in blood and urine samples received from human subjects. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional research committee and were approved by institutional ethical committee of Pt. J. N. M. Medical College and Hospital, Raipur, CG and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed Consent

Written informed consent was obtained from the parent or the legal guardian and assent was obtained from the subjects for all individual participants included in the study.


  1. 1.
    Mahesh KS, Aggarwal A, Bhasker MV, Mukhopadhyay R, Saraswathy KN (2011) Distribution pattern of HbS and β-globin gene hapltypes among Koya Dora tribe of Andhra Pradesh. Int J Hum Genet. 11(2):123–126CrossRefGoogle Scholar
  2. 2.
    Steinberg MH (2008) Sickle cell anemia, the first molecular disease: overwiew of molecular etiology, pathophysiology, and therapeutic approaches. Sci World J 8:1295–1324CrossRefGoogle Scholar
  3. 3.
    Jayachandra S, Agnihotram G, Skaria LK (2013) Renal abnormalities in sickle cell disease. J Clin Biomed Sci 3(3):111–116Google Scholar
  4. 4.
    Hariri E, Mansour A, Alam AE, Daaboul Y, Korjan S, Bahous SA (2018) Sickle cell nephropathy: an update on pathophysiology, diagnosis and treatment. Int Urol Nephrol 50(6):1075–1083CrossRefGoogle Scholar
  5. 5.
    Bolarinwala RA, Akhinlade KS, Kuti MA, Olawale OO, Akinola NO (2012) Renal disease in adult Nigerians with sickle cell anemia: a report of prevalence, clinical features and risk factors. Saudi J Kidney Dis Transpl 23(1):171–175Google Scholar
  6. 6.
    Saraf SL, Zhang X, Shah B, Kanias T, Gudehithlu KP, Kittles R, Machado RF, Arruda JAL, Gladwin MT, Singh AK, Gordeuk VR (2015) Genetic variants and cell-free hemoglobin processing in sickle cell nephropathy. Haematologica 100(10):1275–1284CrossRefGoogle Scholar
  7. 7.
    Aleem A (2008) Renal abnormalities in patients with sickle cell disease: a single centre report from Saudi Arabia. Saudi J Kidney Dis Transpl 19:194–199PubMedGoogle Scholar
  8. 8.
    Hirschberg R (2010) Glomerular hyperfilteration in sickle cell disease. Clin J Am Soc Nephrol 5:748–749CrossRefGoogle Scholar
  9. 9.
    Allon M (1990) Renal abnormalities in sickle cell disease. Arch Intern Med 150:501–504CrossRefGoogle Scholar
  10. 10.
    Amle D, Mir R, Khaneja A, Agarwal S, Ahlawat R, Ray PC, Saxena A (2015) Association of 18 bp insertion/deletion polymorphism at − 2549 position of VEGF gene with diabetic nephropathy in type 2 diabetes mellitus patients of North Indian population. J Diabetes Metab Disord 14:19CrossRefGoogle Scholar
  11. 11.
    Yang B, Cross DF, Ollerenshaw M, Millward BA, Demaine AG (2003) Polymorphisms of the vascular endothelial growth factor and susceptibility to diabetic microvascular complications in patients with type 1 diabetes mellitus. J Diabetes Complications 17:1–6CrossRefGoogle Scholar
  12. 12.
    Buraczynska M, Ksiazek P, Baranowicz-Gaszczyk I, Jozwiak L (2007) Association of the VEGF gene polymorphism with diabetic retinopathy in type 2 diabetic patients. Nephrol Dial Transpl 22(3):827–832CrossRefGoogle Scholar
  13. 13.
    Stevens A, Soden J, Brenchley PE, Ralph S, Ray DW (2003) Haplotype analysis of the polymorphic human vascular endothelial growth factor gene promoter. Cancer Res 63:812–816PubMedGoogle Scholar
  14. 14.
    Shahbazi M, Fryer AA, Pravica V, Brogan IJ, Ramsay HM, Hutchinson IV, Harden PN (2002) Vascular endothelial growth factor gene polymorphisms are associated with acute renal allograft rejection. J Am Soc Nephrol 13:260–264PubMedGoogle Scholar
  15. 15.
    Marsh S, Nakhoul FM, Skorecki K, Rubin A, Miller BP, Leibu R, Levy NS, Levy AP (2003) Hypoxic induction of vascular endothelial growth factor is markedly decreased in diabetic individuals who do not develop retinopathy. Diabetes Care 23:1375–1380CrossRefGoogle Scholar
  16. 16.
    Nath KL, Hebbel RP (2015) Sickle cell disease: renal menifestations and mechanisms. Nat Rev Nephrol 11(3):161–171CrossRefGoogle Scholar
  17. 17.
    Simon M, Rockl W, Horning C, Grone EF, Theis H, Weich HA, Fuchs E, Yavon A, Grone HJ (1998) Receptors of vascular endothelial growth factor/vascular permeability factor (VEGF/VPF) in fetal and adult human kidney: localization and [125I]-VEGF bindingsites. J Am Soc Nephrol 9:1032–1044PubMedGoogle Scholar
  18. 18.
    He Y, Ni J, Chen S, Jiang Y, Jia S, Gao Y (2010) The vascular endothelial growth factor-2549 insertion/deletion polymorphism is not associated with susceptibility to hepatocellular carcinoma in Chinese. DNA Cell Biol 29(7):393–396CrossRefGoogle Scholar
  19. 19.
    Stoian A, Bacarea A, Motataianu A, Stoin A, Gliga F, Bacarea V, Carmen D, Banescu C (2014) Vascular endothelial growth factor insertion/deletion gene polymorphism in patients with type 2 diabetes and diabetic peripheral polyneuropathy. Rom Rev Lab Med 22(2):165–172Google Scholar
  20. 20.
    Awata T, Inoue K, Kurihara S, Ohkubo T, Watanabe M, Inukai K, Inoue I, Katayama S (2002) A common polymorphism in the 5′- untranslated region of the VEGF gene is associated with diabetic retinopathy in type 2 diabetes. Diabetes 51:1635–1639CrossRefGoogle Scholar
  21. 21.
    Bleda S, Haro JD, Varela C, Esparza L, Ferruelo A, Acin F (2012) Vascular endothelial growth factor polymorphisms are involved in the late vascular complications in type II diabetic patients. Diab Vasc Dis Res 9(1):68–74CrossRefGoogle Scholar
  22. 22.
    Guasch A, Navarrete J, Nass K et al (2006) Glomerular involvement in adults with sickle cell hemoglobinopathies: prevalence and clinical correlates of progressive renal failure. J Am Soc Nephrol 17(8):2228–2235CrossRefGoogle Scholar
  23. 23.
    Gupta AK, Kirchner KA, Nicholson R et al (1991) Effects of alpha-thalassemia and sickle polymerization tendency on the urine-concentrating defect of individuals with sickle cell trait. J Clin Invest. 88(6):1963–1968 (Experimental study of the effect of alpha-thalassemia on hyposthenuria in SCT) CrossRefGoogle Scholar
  24. 24.
    Lebensburger J, Johnson SM, Askenazi DJ et al (2011) Protective role of hemoglobin and fetal hemoglobin in early kidney disease for children with sickle cell anemia. Am J Hematol 86(5):430–432CrossRefGoogle Scholar
  25. 25.
    Geard A, Pule G, Chetcha Chemegni B, Ngo Bitoungui V, Kengne A, Chimusa E et al (2017) Clinical and genetic predictors of renal dysfunctions in sickle cell anaemia in Cameroon. Br J Haematol 178(4):629–639CrossRefGoogle Scholar
  26. 26.
    Naik R, Derebail V (2017) The spectrum of sickle hemoglobin-related nephropathy: from sickle cell disease to sickle trait. Expert Rev Hematol 10(12):1087–1094CrossRefGoogle Scholar

Copyright information

© Indian Society of Hematology and Blood Transfusion 2018

Authors and Affiliations

  1. 1.Department of BiochemistryPt. J.N.M. Medical CollegeRaipurIndia
  2. 2.Department of BiochemistryCIMSBilaspurIndia

Personalised recommendations